Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TACE-2: A Randomized Placebo-Controlled, Double Blinded, Phase III Trial of Sorafenib in Combination With Transarterial Chemoembolization in Hepatocellular Cancer

NCT01324076 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT01324076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01324076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TACE-2: A Randomized Placebo-Controlled, Double Blinded, Phase III Trial of Sorafenib in Combination With Transarterial Chemoembolization in Hepatocellular Cancer
Lead sponsor
University College, London
Phase
Phase 3
Overall status
Unknown status
Start date
November 30, 2010
Completion date
Not reported
Enrollment
412 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

liver cancer